ZOTA
Zota Health Care LImited (ZOTA) Stock Analysis
Zota Health Care Limited manufactures and markets pharmaceutical products, APIs, and wellness items in India. It focuses on gynaecology, orthopaedics, and specialty therapies through domestic marketing. The company exports formulations to emerging markets. It is listed on Indian stock exchanges.
Healthcare › Biotechnology
₹1,324.10
+4.44% 1W | -7.90% 52W
Market Cap
4.6k CR
P/E Ratio
–
52W High
₹1740
52W Low
₹1022
Div. Yield
0.08%
Beta
0.4
50 DMA
₹1188
200 DMA
₹1257.5
Profit Margin
-17%
Inst. Own.
1.4%
📈 CONSOLIDATING UP
📈 CONSOLIDATING UP
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39 | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 | 129 | 143 | 163 | 174 |
| Expenses | 37 | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 | 123 | 143 | 154 | 185 |
| Operating Profit | 1 | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 | 6 | -0 | 9 | -12 |
| OPM % | 3.3% | 10% | 7% | -3.0% | -2.2% | -1.3% | -8% | 2.5% | 3.8% | 4.9% | -0.3% | 5% | -7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | -3 | 2 |
| Interest | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 | 5 | 5 | 6 |
| Depreciation | 3 | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 | 19 | 22 | 27 | 28 |
| Profit before tax | -3 | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 | -14 | -26 | -26 | -44 |
| Tax % | 1% | 49% | 7% | -27% | 5% | -4% | 2% | -10% | 5% | 13% | 14% | -45% | 1% |
| Net Profit | -3 | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 | -16 | -30 | -14 | -44 |
| EPS in Rs | -1.13 | -0.64 | -1.14 | -2.68 | -4.79 | -4.41 | -6.78 | -4.50 | -4.81 | -5.20 | -8.73 | -4.09 | -12.58 |
| Metric | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 538 | 609 |
| Expenses | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 520 | 606 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | 19 | 3 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 4.8% | 0.6% | 11% | 5% | 4.2% | -2.0% | 3.4% | 0.5% |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 3 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 17 | 20 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 82 | 96 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | -0 | 12 | -5 | -16 | -58 | -80 | -110 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | -2% | -7% | |
| Net Profit | 2 | 2 | 3 | 4 | 6 | 3 | -0 | 9 | -6 | -14 | -57 | -74 | -104 |
| EPS in Rs | 2.17 | 1.43 | 1.85 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -19.70 | -21.35 | -30.60 |
| Dividend Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1,170% | 42% | -44% | -18% | -5% | -5% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 57.0% | 38.0% | – |
Shareholding Pattern
Promoters57.42%
FIIs3.82%
DIIs4.25%
Public34.52%
Promoters55.81%
FIIs3.49%
DIIs4.95%
Public35.75%
Promoters50.64%
FIIs8.09%
DIIs7.22%
Public34.06%
Promoters49.38%
FIIs8.21%
DIIs6.40%
Public36.00%
Promoters49.38%
FIIs7.92%
DIIs6.75%
Public35.96%
Promoters68.12%
Public31.88%
Promoters66.15%
Public33.85%
Promoters59.72%
FIIs0.87%
DIIs3.08%
Public36.33%
Promoters49.38%
FIIs8.21%
DIIs6.40%
Public36.00%
Promoters49.38%
FIIs7.92%
DIIs6.75%
Public35.96%
ZOTA
Holdings Analysis
Key strengths & risk signals
57
Overall
40
Fundamental
74
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
WEAK YEAR! Stock declined 7.9% in the last year.
Strengths (3)
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 150,795 vs down days: 60,071. Ratio: 2.51x
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
STRONG POSITION! Current price (1324.1) is above both moving averages.
Fundamental & Technical Analysis
57Overall
40Fundamental
74Technical
Fundamental Breakdown
Growth Quality
17/30
Revenue CAGR: 56.7% (EXCELLENT, 15/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -17.0% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.08% yield - little to no income.
Debt to Equity
6/10
MODERATE DEBT! D/E of 0.61 - acceptable leverage.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 31.84% public ownership - moderate retail influence.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (1188.0) is below 200-day average (1257.5) - negative signal.
Price Position
8/10
STRONG POSITION! Current price (1324.1) is above both moving averages.
Trend Pattern
14/20
Current trend: CONSOLIDATING UP
52W Performance
3/10
WEAK YEAR! Stock declined 7.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 150,795 vs down days: 60,071. Ratio: 2.51x
RSI
3/5
NEUTRAL! RSI at 59.8 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 42.1% of 52W range - neutral zone.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 4.4% (1 week), 18.8% (1 month), -7.0% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
ZOTA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-29 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-03 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZOTA | ₹1,324.10 | – | -17.0% | 56.7% | – | -7.9% | 57 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| DCAL | ₹149.70 | 145.3 | 0.6% | 9.0% | 21.0% | -50.1% | 55 | BOUNCE FROM SUPPORT | -347.9% | -367.3% | -4.2% | -20.4% |
| PANACEABIO | ₹345.20 | – | -1.1% | 10.1% | – | -17.9% | 49 | BOUNCE FROM SUPPORT | -42.5% | +360.0% | +19.7% | +19.7% |
| HALEOSLABS | ₹1,563.70 | 29.9 | 4.9% | 0.3% | 14.7% | +41.6% | 69 | BREAKOUT | -38.1% | +550.0% | -11.6% | -2.9% |
| LYKALABS | ₹72.70 | – | -6.6% | 13.3% | – | -21.3% | 50 | BREAKDOWN | +133.3% | -127.6% | +28.2% | +51.1% |
| SUPRIYA | ₹847.60 | 34.4 | 22.7% | 21.2% | 32.5% | +23.4% | 83 | BOUNCE FROM SUPPORT | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹514.60 | 38 | 26.5% | 9.4% | 15.7% | -17.2% | 73 | BOUNCE FROM SUPPORT | -14.1% | +21.8% | -17.4% | +24.9% |
| 3BBLACKBIO | ₹1,586.40 | 24.1 | 36.3% | 31.9% | 32.2% | +40.7% | 76 | CONSOLIDATING UP | -24.6% | -1.0% | +50.9% | -5.4% |
Data from TradeAlone · Updated daily
ZOTA News
